Second-Line Treatment of Patients With EGFR-Mutated NSCLC

Following a review of the MARIPOSA-2 trial, experts on non–small cell lung cancer discuss treatment approaches in the second line.

EP: 1.Biomarker Testing in Non–Small Cell Lung Cancer

EP: 2.NSCLC: Molecular Testing in the Metastatic Setting

EP: 3.NGS Testing Challenges and Considerations in NSCLC

EP: 4.Frontline Treatment for EGFR-Mutated Lung Cancer

EP: 5.FLAURA2: Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

EP: 6.MARIPOSA: First-Line Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC

Now Viewing

EP: 7.Second-Line Treatment of Patients With EGFR-Mutated NSCLC

EP: 8.Treatment Landscape for NSCLC With EGFR Exon 20 Insertion Mutations

EP: 9.NSCLC with EGFR Exon 20 Insertions: Updated Data from PAPILLON

EP: 10.Unmet Needs and Future Perspectives on the Treatment of EGFR-Mutated NSCLC

EP: 11.Preferred Treatment Options for EGFRMutated Exon 20 Insertion+ NSCLC

Recent Videos

Related Content

---

Preferred Treatment Options for EGFRMutated Exon 20 Insertion+ NSCLC

ONCOLOGY Staff

June 15th 2024

Article

A recent Training Academy focused on the advancements of treatment for patients with NSCLC EGFR mutations and exon 20 insertions.

Related Content

---

Preferred Treatment Options for EGFRMutated Exon 20 Insertion+ NSCLC

ONCOLOGY Staff

June 15th 2024

Article

A recent Training Academy focused on the advancements of treatment for patients with NSCLC EGFR mutations and exon 20 insertions.